On June 12, Innovent Biologics rose 3.22% in regular trading, trading at HK$74.45/share, with turnover of HK$228 million. The stock is rebounding after consecutive trading sessions of decline driven by regulatory uncertainty surrounding its US$10.5 billion strategic collaboration with Pfizer, which had sent shares from approximately HK$79.5 down to HK$72.1 over the prior week.

The broader biotech sector is showing signs of stabilization today, with Akeso up 1.71%, BeiGene up 0.64%, Remegen up 1.0%, and SKB Bio up 3.8%, providing supportive sentiment after days of systematic selling pressure. Additionally, Innovent recently secured priority review acceptance from China's NMPA for its CLDN18.2 ADC drug IBI343 in advanced gastric cancer, becoming the first globally to enter regulatory review in this target class, and presented multiple clinical results at the ADA annual meeting for its obesity and metabolic disease pipeline.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)